Literature DB >> 20188793

Restoration of mutant cytochrome P450 reductase activity by external flavin.

Catherine Nicolo1, Christa E Flück, Primus E Mullis, Amit V Pandey.   

Abstract

Cytochrome P450 oxidoreductase (POR) supplies electrons from NADPH to steroid and drug metabolizing reactions catalyzed by the cytochrome P450s located in endoplasmic reticulum. Mutations in human POR cause a wide spectrum of disease ranging from disordered steroidogenesis to sexual differentiation. Previously we and others have shown that POR mutations can lead to reduced activities of steroidogenic P450s CYP17A1, CYP19A1 and CYP21A1. Here we are reporting that mutations in the FMN binding domain of POR may reduce CYP3A4 activity, potentially influencing drug and steroid metabolism; and the loss of CYP3A4 activity may be correlated to the reduction of cytochrome b(5) by POR. Computational molecular docking experiments with a FMN free structural model of POR revealed that an external FMN could be docked in close proximity to the FAD moiety and receive electrons donated by NADPH. Using FMN supplemented assays we have demonstrated restoration of the defective POR activity in vitro. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188793     DOI: 10.1016/j.mce.2010.02.024

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  19 in total

1.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

2.  Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.

Authors:  Yi Jin; Mo Chen; Trevor M Penning; Walter L Miller
Journal:  Biochem J       Date:  2015-05-15       Impact factor: 3.857

3.  Molecular dynamics simulations give insight into the conformational change, complex formation, and electron transfer pathway for cytochrome P450 reductase.

Authors:  Axel Sündermann; Chris Oostenbrink
Journal:  Protein Sci       Date:  2013-08-01       Impact factor: 6.725

4.  Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.

Authors:  Karen M McCammon; Satya P Panda; Chuanwu Xia; Jung-Ja P Kim; Daniela Moutinho; Michel Kranendonk; Richard J Auchus; Eileen M Lafer; Debashis Ghosh; Pavel Martasek; Rekha Kar; Bettie Sue Masters; Linda J Roman
Journal:  J Biol Chem       Date:  2016-08-05       Impact factor: 5.157

5.  Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Authors:  Xiuling Zhang; Lei Li; Xinxin Ding; Laurence S Kaminsky
Journal:  Drug Metab Dispos       Date:  2011-05-11       Impact factor: 3.922

6.  Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization.

Authors:  Christopher C Marohnic; Warren J Huber Iii; J Patrick Connick; James R Reed; Karen McCammon; Satya P Panda; Pavel Martásek; Wayne L Backes; Bettie Sue S Masters
Journal:  Arch Biochem Biophys       Date:  2011-06-28       Impact factor: 4.013

7.  Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency.

Authors:  Chuanwu Xia; Satya P Panda; Christopher C Marohnic; Pavel Martásek; Bettie Sue Masters; Jung-Ja P Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

8.  Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations.

Authors:  Mária Tomková; Christopher C Marohnic; David Gurwitz; Ondřej Seda; Bettie Sue Siler Masters; Pavel Martásek
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

9.  Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.

Authors:  Dorota Tomalik-Scharte; Dominique Maiter; Julia Kirchheiner; Hannah E Ivison; Uwe Fuhr; Wiebke Arlt
Journal:  Eur J Endocrinol       Date:  2010-09-15       Impact factor: 6.664

Review 10.  NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family.

Authors:  Takashi Iyanagi; Chuanwu Xia; Jung-Ja P Kim
Journal:  Arch Biochem Biophys       Date:  2012-09-11       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.